The de ritis ratio: the test of time.

Q1 Biochemistry, Genetics and Molecular Biology
Clinical Biochemist Reviews Pub Date : 2013-11-01
Mona Botros, Kenneth A Sikaris
{"title":"The de ritis ratio: the test of time.","authors":"Mona Botros, Kenneth A Sikaris","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>De Ritis described the ratio between the serum levels of aspartate transaminase (AST) and alanine transaminase (ALT) almost 50 years ago. While initially described as a characteristic of acute viral hepatitis where ALT was usually higher than AST, other authors have subsequently found it useful in alcoholic hepatitis, where AST is usually higher than ALT. These interpretations are far too simplistic however as acute viral hepatitis can have AST greater than ALT, and this can be a sign of fulminant disease, while alcoholic hepatitis can have ALT greater than AST when several days have elapsed since alcohol exposure. The ratio therefore represents the time course and aggressiveness of disease that would be predicted from the relatively short half-life of AST (18 h) compared to ALT (36 h). In chronic viral illnesses such as chronic viral hepatitis and chronic alcoholism as well as non-alcoholic fatty liver disease, an elevated AST/ALT ratio is predictive of long terms complications including fibrosis and cirrhosis. There are methodological issues, particularly whether or not pyridoxal phosphate is used in the transaminase assays, and although this can have specific effects when patient samples are deficient in this vitamin, these method differences generally have mild effects on the usefulness of the assays or the ratio. Ideally laboratories should be using pyridoxal phosphate supplemented assays in alcoholic, elderly and cancer patients who may be pyridoxine deplete. Ideally all laboratories reporting abnormal ALT should also report AST and calculate the De Ritis ratio because it provides useful diagnostic and prognostic information. </p>","PeriodicalId":34924,"journal":{"name":"Clinical Biochemist Reviews","volume":"34 3","pages":"117-30"},"PeriodicalIF":0.0000,"publicationDate":"2013-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866949/pdf/cbr-34-117.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Biochemist Reviews","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

De Ritis described the ratio between the serum levels of aspartate transaminase (AST) and alanine transaminase (ALT) almost 50 years ago. While initially described as a characteristic of acute viral hepatitis where ALT was usually higher than AST, other authors have subsequently found it useful in alcoholic hepatitis, where AST is usually higher than ALT. These interpretations are far too simplistic however as acute viral hepatitis can have AST greater than ALT, and this can be a sign of fulminant disease, while alcoholic hepatitis can have ALT greater than AST when several days have elapsed since alcohol exposure. The ratio therefore represents the time course and aggressiveness of disease that would be predicted from the relatively short half-life of AST (18 h) compared to ALT (36 h). In chronic viral illnesses such as chronic viral hepatitis and chronic alcoholism as well as non-alcoholic fatty liver disease, an elevated AST/ALT ratio is predictive of long terms complications including fibrosis and cirrhosis. There are methodological issues, particularly whether or not pyridoxal phosphate is used in the transaminase assays, and although this can have specific effects when patient samples are deficient in this vitamin, these method differences generally have mild effects on the usefulness of the assays or the ratio. Ideally laboratories should be using pyridoxal phosphate supplemented assays in alcoholic, elderly and cancer patients who may be pyridoxine deplete. Ideally all laboratories reporting abnormal ALT should also report AST and calculate the De Ritis ratio because it provides useful diagnostic and prognostic information.

Abstract Image

Abstract Image

de ritis 比率:时间的考验。
De Ritis 在近 50 年前描述了血清中天冬氨酸转氨酶 (AST) 和丙氨酸转氨酶 (ALT) 的比值。虽然最初被描述为急性病毒性肝炎的特征,即 ALT 通常高于 AST,但其他作者随后发现它对酒精性肝炎也很有用,因为酒精性肝炎的 AST 通常高于 ALT。但是,这些解释过于简单,因为急性病毒性肝炎的 AST 可能高于 ALT,这可能是疾病暴发的征兆,而酒精性肝炎在接触酒精数天后,ALT 可能高于 AST。因此,该比值代表的是 AST(18 小时)与 ALT(36 小时)相比相对较短的半衰期所预测的病程时间和病情严重程度。在慢性病毒性疾病(如慢性病毒性肝炎、慢性酒精中毒以及非酒精性脂肪肝)中,AST/ALT 比值升高可预测纤维化和肝硬化等长期并发症。转氨酶检测存在方法问题,特别是是否使用磷酸吡哆醛,尽管当患者样本缺乏这种维生素时会产生特定影响,但这些方法差异通常对检测或比值的实用性影响较小。对于可能缺乏吡哆醇的酗酒者、老年人和癌症患者,实验室最好使用补充磷酸吡哆醛的检测方法。理想情况下,所有报告谷丙转氨酶(ALT)异常的实验室也应报告谷草转氨酶(AST),并计算 De Ritis 比值,因为它能提供有用的诊断和预后信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Biochemist Reviews
Clinical Biochemist Reviews Biochemistry, Genetics and Molecular Biology-Clinical Biochemistry
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信